Description: In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth and addressed safety concerns surrounding its Librela osteoarthritis treatment that some veterinarians continue to prescribe when they judge benefits to outweigh risks. At the same time, CEO Kristin Peck highlighted rising demand for livestock vaccines and a broad pipeline spanning chronic kidney disease, oncology, cardiology, obesity, metabolic disease, and anxiety in...

Description: Zoetis (ZTS) reached $125.32 at the closing of the latest trading day, reflecting a -1.45% change compared to its last close.

Description: Zoetis CEO Kristin Peck says higher protein demand is driving demand for livestock vaccines. She speaks with Katie Greifeld at JPMorgan's annual health-care conference in San Francisco.

Description: Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The fund focuses on investing in equities globally. The T Class Accumulation shares where the firm invested returned 0.8% in 2025, compared to 12.8% for the […]

Description: Dublin, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Infectious Disease Diagnostics Market - A Global and Regional Analysis: Focus on Technology, Product, Animal Type, Infection Type, End user, Country, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.One of the key drivers of the veterinary infectious disease diagnostics market is the rising prevalence of zoonotic diseases. Zoonotic diseases those transmitted from animals to humans pose sig

Description: UTHR vs. ZTS: Which Stock Is the Better Value Option?

Description: If you are wondering whether Zoetis is offering good value at its current price, this article explains what the numbers may indicate about the stock. Zoetis recently closed at US$129.37, with returns of 2.3% over the last week, 9.0% over the last month, 2.7% year to date, a 19.8% decline over the last year, a 13.5% decline over three years, and an 18.5% decline over five years. Recent news coverage around Zoetis has focused on its position in animal health and its role as a major pure play...

Description: It's not time to give up on these companies yet.

Description: Zoetis Inc. (NYSE:ZTS) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 15, BofA downgraded Zoetis Inc. (NYSE:ZTS) to Neutral from Buy and lowered its price target to $135 from $165. In other news, on December 5, Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for […]

Description: PARSIPPANY, N.J., December 30, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts.

Description: Zoetis Inc. (NYSE:ZTS) is included among the 15 Dividend Stocks with Low Payout Ratios and Strong Upside. On December 18, Morgan Stanley lowered its price target on Zoetis Inc. (NYSE:ZTS) to $160 from $175 and kept an Overweight rating. In its year-ahead outlook, the firm said healthcare technology and providers offer an “attractive backdrop for […]

Description: Zoetis (ZTS) closed at $123.78 in the latest trading session, marking a +1.26% move from the prior day.

Description: Cattle placed in US feedlots, where animals are fed until ready to be slaughtered, dropped 11% from a year ago to a record low for November, according to a US Department of Agriculture report Friday. It’s also setting the slate for more expensive American steaks for longer, complicating President Donald Trump’s efforts to bring down record beef prices. Tyson Foods Inc., the country’s biggest meatpacker, underscored the difficulties for the industry last month as it announced it would close a Nebraska beef plant and reduce operations to one shift at a facility in Texas roughly 450 miles from the Mexican border.

Description: Don't overlook these potential bargain buys -- they may not stay down for long.

Description: PARSIPPANY, N.J., December 18, 2025--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT.

Description: Zoetis (ZTS) just wrapped up a $1.75 billion convertible senior notes deal, and that financing move is really the key to understanding where the stock could head next from here. See our latest analysis for Zoetis. Despite the flurry of news, including a 6% dividend hike and new pain therapy approvals, Zoetis shares now trade around $122.28, with a year to date share price return of roughly negative 25% and a one year total shareholder return also firmly negative. This suggests sentiment has...

Description: Zoetis Inc. recently completed a US$1.75 billion offering of 0.25% senior unsecured convertible notes due June 15, 2029, primarily to fund share repurchases and capped call transactions. Alongside this financing move, Zoetis approved a 6% increase in its quarterly dividend for early 2026 and advanced its feline osteoarthritis portfolio with Health Canada’s approval of Portela. We’ll now explore how funding buybacks through low‑coupon convertible notes could influence Zoetis’s earnings...

Description: The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

Description: CNP, VAC, PCG and ZTS raised dividends as tech volatility and economic uncertainty push income-focused investors toward steadier stocks.

Description: PARSIPPANY, N.J., December 16, 2025--Zoetis Inc. (NYSE: ZTS) (the "Company" or "Zoetis") today announced that it has priced its previously announced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the "Securities Act"). Zoetis has also granted the initial purchasers of the Notes an

Description: PARSIPPANY, N.J., December 15, 2025--Zoetis Inc. (NYSE: ZTS) (the "Company" or "Zoetis") today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the "Notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the "Securities Act"). Zoetis also intends to grant the initial purchasers of the Notes an o

Description: Zoetis Inc. ( NYSE:ZTS ) will increase its dividend from last year's comparable payment on the 3rd of March to $0.53...

Description: Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader overview of pharmaceutical stocks for 2026. However, the investment bank maintained its earlier Buy rating for the shares. It […]

Description: If you are wondering whether Zoetis is starting to look like a bargain after its big pullback, you are not alone. This piece will walk through whether the current price makes sense for long term investors. The stock has slid to around $117.66, with returns of about -2.3% over the last week, -2.0% over the last month, and a much steeper -27.6% year to date. This has raised fresh questions about whether the market has overreacted to changing expectations. Recently, Zoetis has been in the...

Description: PARSIPPANY, N.J., December 11, 2025--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026.

Description: Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.

Description: ​Zoetis Inc. (NYSE:ZTS) is one of the Good Stocks to Buy According to Analysts. On December 2, Zoetis Inc. (NYSE:ZTS) held its innovation day, highlighting its long-term growth opportunities. In addition, Wall Street maintains a positive outlook on the stock. ​Management noted that the animal health market is anticipated to grow nearly double the current […]

Description: Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

Description: PARSIPPANY, N.J., December 05, 2025--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation.

Description: Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: We came across a bullish thesis on Zoetis Inc. on Value investing subreddit by anonymous_sheep1. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $128.18 as of November 28th. ZTS’s trailing and forward P/E were 21.58 and 19.49 respectively according to Yahoo Finance. Zoetis Inc. engages in the discovery, development, […]

Description: ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.

Description: PARSIPPANY, N.J., December 02, 2025--Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health.

Description: Zoetis (ZTS) has just secured marketing authorization from the European Commission for Lenivia, its new antibody therapy targeting osteoarthritis pain in dogs. The approval allows Zoetis to offer a three-month pain relief treatment to dog owners in Europe with a single injection. See our latest analysis for Zoetis. News of Lenivia’s approval lands just as Zoetis finds itself at a crossroads. While enthusiasm for its innovation pipeline has brought flashes of short-lived optimism, as seen in a...

Description: Zoetis stock has seen its fair value target decrease slightly, moving from $170.63 to $169.96. Recent analyst assessments reflect a more cautious view on near-term prospects. While some analysts remain optimistic about the company’s innovative pipeline, others cite ongoing product and market headwinds that have tempered immediate growth expectations. Stay tuned to discover how investors can monitor the evolving narrative and make informed decisions moving forward. Analyst Price Targets don't...

Description: Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?

Description: In late November 2025, Zoetis Inc. announced that the European Commission granted marketing authorization for Lenivia® (izenive™), a new monoclonal antibody therapy providing up to three months of osteoarthritis pain relief in dogs after a single injection. This marks a significant expansion of Zoetis’s companion animal pain management portfolio, as Lenivia offers a longer duration of action and a novel binding approach compared to existing therapies. We'll take a closer look at how...

Description: These companies' prospects are better than recent performances may suggest.

Description: PARSIPPANY, N.J., November 26, 2025--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.

Description: Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.

Description: Zoetis Inc. (NYSE:ZTS) is one of the most profitable large cap stocks to buy right now. On November 18, Stifel analyst Jonathan Block lowered the firm’s price target on Zoetis to $130 from $140 and kept a Hold rating on the shares. After the release of the company’s Q3 2025 results, Street’s revenue forecasts for […]

Description: Wondering if Zoetis stock is a hidden value or just treading water? You are not alone, especially with all the recent buzz about its share price. After a difficult few months, Zoetis is down nearly 25% year-to-date and over 30% for the past year, despite a small 1% rebound in the last week. These moves follow ongoing headlines about developments in animal health legislation and the company's strategic acquisitions. Both of these factors have shifted investor sentiment, whether you are...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: PARSIPPANY, N.J., November 20, 2025--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts.

Description: PARSIPPANY, N.J., November 19, 2025--Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic), Senior Vice President of Global Therapeutics. As previously announced, Dr. Esch will succeed Dr

Description: Key Insights The projected fair value for Zoetis is US$177 based on 2 Stage Free Cash Flow to Equity Zoetis' US$121...

Description: These cheap dividend stocks would make great cornerstone pieces to any portfolio -- especially for investors looking for a deal in today's somewhat expensive market.

Description: The steep increase in pet healthcare costs have doubled over the past five years, according to NPR. There are a number of reasons for this trend, but the overall numbers are large, reaching $39.8 billion in 2024. Some projections estimate that pet healthcare will swell to $112 billion by 2030. As a result, veterinary healthcare ... Pet Healthcare Spending Is Soaring. These 5 Stocks Are Positioned to Clean Up

Description: CPRX vs. ZTS: Which Stock Is the Better Value Option?

Description: Zoetis, the animal health company, reported higher third quarter earnings and net income for 2025 and reaffirmed its full-year guidance. The company also secured European approval for Portela, expanding its growing monoclonal antibody portfolio for companion animals. See our latest analysis for Zoetis. Despite new product approvals and steady top-line growth, Zoetis shares have seen a sharp downturn, with a 1-year total shareholder return of -31.1% and the share price now sitting at $119.79...

Description: These healthcare heavyweights have tumbled, causing abnormally high dividend yields.

Description: Zoetis faced a challenging third quarter, with the market reacting negatively to results that showed flat year-on-year sales and a trim to full-year revenue guidance. Management attributed the muted performance primarily to subdued clinic visits in the U.S. companion animal segment and heightened promotional activity from competitors. CEO Kristin Peck noted, “Growth moderated this quarter driven by a strong year-over-year comp and macro factors, including vet clinic visits and promotional activi

Description: Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Description: It's been a sad week for Zoetis Inc. ( NYSE:ZTS ), who've watched their investment drop 17% to US$120 in the week since...

Description: These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.

Description: Exploring Diamond Hill Capital (Trades, Portfolio)'s Latest 13F Filing for Q3 2025

Description: We recently published 10 Stocks Lead Wall Street Downward Spiral. Zoetis Inc. (NYSE:ZTS) is one of the worst-performing stocks on Tuesday. Zoetis fell to a new 52-week low on Tuesday, as investor sentiment was dampened by a lower revenue growth outlook for full-year 2025. In intra-day trading, Zoetis Inc. (NYSE:ZTS) dropped to its lowest price […]

Description: The Morning Bull - US Market Morning Update Wednesday, Nov, 5 2025 US stock futures drift lower ahead of the open as investors grapple with a fresh dip in economic sentiment and wavering confidence around Federal Reserve rate cuts. An unexpected surge in crude oil inventories and dropping Treasury yields have heightened concerns about slowing growth and rising financial stress. This has put pressure on the broader market as investors weigh the odds of near-term turbulence. Today's volatility...

Description: Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.

Description: Zoetis (ZTS) posted net profit margins of 28.2%, up from 26.6% last year, reflecting stronger profitability this period. Earnings have grown at 8.5% per year over the past five years, with a strong 9.1% uptick in the most recent year, outpacing the company’s historical average. Looking ahead, analysts expect annual earnings growth of 7.4%, trailing the broader US market’s 16% forecast, while revenue is projected to rise 5.2% per year, slower than the US average. Despite trading at a premium...

Description: Zoetis stock took a hit Tuesday after the animal health outlet slashed its 2025 sales outlook on the back of "broader macro trends."

Description: Zoetis Inc (ZTS) reports steady revenue growth and strategic investments, while addressing challenges in the companion animal and dermatology segments.

Description: Shares of animal health company Zoetis (NYSE:ZTS) fell 12.6% in the morning session after the company reported mixed third-quarter results and cut its full-year sales forecast. Although its adjusted earnings of $1.70 per share beat Wall Street's estimates, revenue of $2.4 billion was flat year-over-year and met expectations. More concerning for investors, Zoetis lowered its full-year revenue guidance to a midpoint of $9.44 billion, a 0.9% decrease from its previous forecast. The company's operat

Description: Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.

Description: Zoetis Inc. recently received European Commission approval for Portela, a monoclonal antibody therapy offering three-month pain relief for cats with osteoarthritis, making it the first of its kind in the region. This approval not only grows Zoetis' companion animal therapeutic lineup but also highlights the company's ongoing innovation in animal health care solutions. We'll explore how this regulatory milestone may impact Zoetis' investment narrative, particularly by advancing its pipeline...

Description: The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Shares of Zoetis slumped Tuesday after the animal healthcare company reported weaker-than-expected quarterly revenue and slashed its full-year outlook. The company posted adjusted earnings of $1.70 a share for the third quarter, above analysts’ consensus estimates of $1.62. Zoetis saw a particularly steep decline in revenue for its swine and poultry medicines.

Description: Zoetis (ZTS) delivered earnings and revenue surprises of +4.94% and -0.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.

Description: The Parsippany, New Jersey-based company said it had net income of $1.63 per share. Earnings, adjusted for non-recurring costs, were $1.70 per share. The results surpassed Wall Street expectations.

Description: PARSIPPANY, N.J., November 04, 2025--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.

Description: The global veterinary monoclonal antibodies market is set to surge, reaching USD 3.06 billion by 2030, up from USD 1.70 billion in 2025, with a CAGR of 12.4%. This growth is driven by increasing pet ownership and heightened awareness of chronic diseases in pets. Despite challenges like rising pet care costs and strict regulations, expanding therapeutic uses offer new opportunities. Notably, the canine segment dominates due to the high incidence of skin conditions in dogs. By 2030, the subcutaneo

Description: Idexx Laboratories catapulted to a record high Monday after the vet diagnostics outlet beat quarterly forecasts and boosted its 2025 outlook.

Description: PARSIPPANY, N.J., November 03, 2025--Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 20

Description: Some might call them boring businesses, but they have tremendous dividend growth track records.

Description: Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.

Description: Zoetis stock has recently seen its fair value estimate adjusted slightly downward, dropping from $188.83 to $187.70. While the discount rate held steady, the change reflects cautious analyst sentiment as the company heads into its upcoming earnings release. Readers interested in staying informed about the evolving outlook for Zoetis should continue following updates on these narrative shifts. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find...

Description: Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Description: Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

Description: Diamond Hill Capital, an investment management company, released its “Select Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets continued their YTD rally in the third quarter, with the Russell 3000 Index surging 8%. At the same time, the portfolio underperformed the Russell 3000 Index, returning 4.98%. To get […]

Description: ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.

Description: Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: PARSIPPANY, N.J., October 29, 2025--Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats.

Description: Readers hoping to buy Zoetis Inc. ( NYSE:ZTS ) for its dividend will need to make their move shortly, as the stock is...

Description: Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: PARSIPPANY, N.J., October 28, 2025--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board.

Description: Zoetis (ZTS) concluded the recent trading session at $147.53, signifying a +1.09% move from its prior day's close.

Description: GRFS vs. ZTS: Which Stock Is the Better Value Option?

Description: If you’re holding Zoetis stock or thinking about jumping in, it’s hard not to notice the recent shifts in its performance. Over the last week, shares have nudged upward by 1.3%, and in the past month, they're up 3.0%. But take a step back and the picture grows more complex: Zoetis is still down 10.3% year-to-date and 17.9% over the last year. For a global leader in animal health, that’s quite a ride. Those longer-term dips could signal to some that there’s now less optimism baked into the...

Description: We came across a bullish thesis on Zoetis Inc. on Summit Stocks’s Substack. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $142.26 as of October 13th. ZTS’s trailing and forward P/E were 25.21 and 21.69 respectively according to Yahoo Finance. Zoetis is the global leader in animal pharmaceuticals, […]

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: Zoetis is set to post its third-quarter results next month, and analysts project a single-digit earnings rise.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.